Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 16/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5685834 | 0.78 | ADORA2B (0.45) | ADORA2BADORA1ADORA3ADORA2ASCD | |
| SCHEMBL1697136 | 0.73 | ADORA2B (0.47) | ADORA2BADORA1ADORA3ADORA2AALK | |
| SCHEMBL2327640 | 0.71 | ADORA2B (0.62) | ADORA2BADORA1ADORA3ADORA2AKDM1A | |
| SCHEMBL4639698 | 0.67 | DAO (0.36) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL243045 | 0.66 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL13995583 | 0.65 | ADORA2B (0.75) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL1945245 | 0.64 | ADORA2B (1.00) | ADORA2BADORA1ADORA3ADORA2A | |
| SCHEMBL25583879 | 0.64 | SCD (0.53) | ADORA2BADORA1ADORA3ADORA2ASCD | |
| SCHEMBL29281237 | 0.62 | SCD (0.52) | ADORA2BADORA1ADORA3ADORA2ASCD | |
| SCHEMBL1946751 | 0.62 | L3MBTL1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444233-B1 | A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD PALO ALTO INC (US) | 2011-08-17 | — | — | EP | disclosed |